Since the medicine's first approval in 2016, nearly 130,000 people in the U.S. have been treated with Taltz "Taltz has long delivered effective treatment with a well-established safety profile that ...

At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...

Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced ...

TORONTO, June 05, 2020 (GLOBE NEWSWIRE) -- TALTZ ® (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data presented virtually ...

The phase 3b TOGETHER-PsA trial evaluated the safety and efficacy of concomitant ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

On Thursday, Eli Lilly and Co. (NYSE: LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with concomitant ixekizumab and tirzepatide met PsA and weight reduction endpoints. Safety data ...

Eli Lilly’s best-selling weight loss drug, Zepbound (tirzepatide), has scored again, this time in a late-stage trial alongside the company’s plaque psoriasis drug, Taltz (ixekizumab). During the Phase ...

INDIANAPOLIS, June 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data for Taltz ® (ixekizumab), Olumiant ® (baricitinib) and mirikizumab at the 24th World Congress of ...

INDIANAPOLIS, Aug. 8, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the availability of a new, citrate-free formulation of Taltz ® (ixekizumab) injection 80 mg/mL. The new ...

At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to =10% weight reduction with concomitant Taltz and ...